Table 2 Prognostic factors for in-field control by Cox proportional-hazards model.

From: Prognostic Significance of Apparent Diffusion Coefficient in Hepatocellular Carcinoma Patients treated with Stereotactic Ablative Radiotherapy

Variable

Univariable

Multivariable

HR (95% CI)

p

HR (95% CI)

p

Tumor size (1 cm increase)

1.22 (1.07–1.38)

0.002

1.19 (1.05–1.34)

0.006

Portal vein tumor thrombosis

5.79 (1.51–22.3)

0.011

  

AFP level, ≥200 vs. <200

3.81 (1.02–14.22)

0.047

  

CTP class, A vs. B

3.06 (0.38–24.70)

0.294

  

EQD2 (Gy), >71.3 vs. ≤71.3

1.03 (0.28–3.88)

0.963

  

1st MRI mRECIST response

    

     responding lesion

0.37 (0.10–1.41)

0.145

  

Pre-SABR ADC (×10−3 mm2/s)

    

     >1.45 vs. ≤1.45

1.77 (0.44–7.08)

0.423

  

Post-SABR ADC change

    

     any ADC increment

0.75 (0.16–3.63)

0.723

  

     ≥25% ADC increment

0.09 (0.01–0.72)

0.023

0.11 (0.01–0.88)

0.037

  1. Abbreviation: AFP = α-fetoprotein; CTP = Child-Turcotte-Pugh liver function scale; EQD2 = equivalent dose of 2 Gy per fraction; mRECIST = modified Response Evaluation Criteria in Solid Tumors; SABR = stereotactic ablative radiotherapy; ADC = apparent diffusion coefficient.